retatrutide clinical trial data Triple hormone receptor agonist for metabolic dysfunction-associated steatotic liver disease: a randomized phase 2a Retatrutide Phase 3: TRIUMPH Program

A review of practical issues on the use of glucagon-like peptide-1 receptor agonists for the management of type 2 diabetes

pylori Breath and Stool Testing

It is licensed in the United States (under the brand name Egrifta) for HIV-associated lipodystrophy but has not been approved by the MHRA for any indication

Investigators have examined the compound in published Phase 2 trials covering obesity, type 2 diabetes, and metabolic dysfunction-associated steatotic liver disease

The winner may be the company that best balances efficacy, tolerability, supply, pricing, payer coverage, and patient persistence

Eating smaller meals, avoiding heavy or spicy foods, and staying well-hydrated can help relieve these symptoms